Spire Healthcare Group (LON:SPI) Stock Price Down 21.4% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI)’s share price fell 21.4% on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 176.40 ($2.28). 3,426,506 shares traded hands during trading, an increase of 447% from the average session volume of 626,257 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The stock has a market cap of £711.58 million, a PE ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The firm has a fifty day moving average of GBX 227.28 and a 200 day moving average of GBX 229.74. The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25.

Spire Healthcare Group (LON:SPI) last posted its earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. On average, equities research analysts anticipate that Spire Healthcare Group plc will post 15.6634747 EPS for the current fiscal year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.